gatifloxacin has been researched along with Bacterial Pneumonia in 24 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 9.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "The efficacies of gatifloxacin and moxifloxacin were assessed in a BALB/c mouse model of pneumonic tularemia and compared with the efficacy of ciprofloxacin." | 7.73 | Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. ( Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J, 2006) |
| "Gatifloxacin 400 mg was administered once daily for seven to 14 days." | 6.70 | Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. ( Gothelf, S; High, KP; Nicholson, SC; Webb, CD, 2002) |
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 5.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "The efficacies of gatifloxacin and moxifloxacin were assessed in a BALB/c mouse model of pneumonic tularemia and compared with the efficacy of ciprofloxacin." | 3.73 | Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. ( Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J, 2006) |
| " The incidence of adverse events was low and the most commonly reported events were nausea and dyspepsia." | 2.70 | Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study. ( Carvalho, CR; Franca, SA, 2002) |
| "Gatifloxacin is an 8-methoxy fluoroquinolone with broad activity against respiratory tract pathogens, including those commonly associated with community-acquired pneumonia (CAP)." | 2.70 | Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. ( Gotfried, M; Gothelf, S; Nicholson, SC; Quinn, TC; Webb, CD; Wikler, MA, 2002) |
| "Gatifloxacin 400 mg was administered once daily for seven to 14 days." | 2.70 | Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. ( Gothelf, S; High, KP; Nicholson, SC; Webb, CD, 2002) |
| " Gatifloxacin is safe and efficacious in adults of any age with community-acquired pneumonia, including the elderly up to 100 years old and patients with S." | 2.70 | Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. ( Gothelf, S; Naughton, BJ; Nicholson, SC; Webb, CD; Wilson, WR, 2002) |
| " Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients." | 1.32 | An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers. ( Nicodemo, AC, 2003) |
| "Gatifloxacin is a new 8-methoxy fluoroquinolone with enhanced activity against gram-positive cocci." | 1.31 | Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ( Andes, D; Craig, WA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 22 (91.67) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lui, KJ | 1 |
| Chang, KC | 1 |
| Franca, SA | 1 |
| Carvalho, CR | 1 |
| Sher, LD | 1 |
| Poole, MD | 1 |
| Von Seggern, K | 1 |
| Wikler, MA | 2 |
| Nicholson, SC | 4 |
| Pankey, GA | 1 |
| Mandell, LA | 2 |
| Gotfried, M | 1 |
| Quinn, TC | 1 |
| Gothelf, S | 3 |
| Webb, CD | 3 |
| High, KP | 1 |
| Wilson, WR | 1 |
| Naughton, BJ | 1 |
| Jones, RN | 1 |
| Nicodemo, AC | 1 |
| Lode, H | 2 |
| Aronkyto, T | 1 |
| Chuchalin, AG | 1 |
| Jaaskevi, M | 1 |
| Kahnovskii, I | 1 |
| Kleutgens, K | 2 |
| Martinez, FJ | 1 |
| Bentzel, DE | 1 |
| Elliott, TB | 1 |
| Keller, CE | 1 |
| Brook, I | 1 |
| Shoemaker, MO | 1 |
| Knudson, GB | 1 |
| Magyar, P | 1 |
| Muir, JF | 1 |
| Loos, U | 1 |
| Uriarte, SM | 1 |
| Molestina, RE | 1 |
| Miller, RD | 1 |
| Bernabo, J | 1 |
| Farinati, A | 1 |
| Eiguchi, K | 1 |
| Ramirez, JA | 1 |
| Summersgill, JT | 1 |
| Mendonça, JS | 1 |
| Yamaguti, A | 1 |
| Corrêa, JC | 1 |
| Badaró, R | 1 |
| Okimoto, N | 1 |
| Kibayashi, T | 1 |
| Mimura, K | 1 |
| Yamato, K | 1 |
| Kurihara, T | 1 |
| Honda, Y | 1 |
| Osaki, K | 1 |
| Asaoka, N | 1 |
| Ohba, H | 1 |
| Dean, NC | 1 |
| Sperry, P | 1 |
| Wikler, M | 1 |
| Suchyta, MS | 1 |
| Hadlock, C | 1 |
| Steward, J | 1 |
| Piercy, T | 1 |
| Lever, MS | 1 |
| Simpson, AJ | 1 |
| Brooks, TJ | 1 |
| Miyashita, N | 1 |
| Niki, Y | 1 |
| Kishimoto, T | 1 |
| Nakajima, M | 1 |
| Matsushima, T | 1 |
| Dresser, LD | 1 |
| Niederman, MS | 1 |
| Paladino, JA | 1 |
| Cannon, CP | 1 |
| McCabe, CH | 1 |
| Belder, R | 1 |
| Breen, J | 1 |
| Braunwald, E | 1 |
| Andes, D | 1 |
| Craig, WA | 1 |
11 trials available for gatifloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study.
Topics: Adult; Aged; Anti-Infective Agents; Brazil; Central Nervous System Diseases; Community-Acquired Infe | 2002 |
Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
Topics: Acute Disease; Aged; Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Dru | 2002 |
Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Community-Acquired Infections; Drug Admini | 2002 |
Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquire | 2002 |
Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquire | 2002 |
A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Community-Acquire | 2004 |
Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bact | 2004 |
Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Community-Acquired Infections; F | 2004 |
Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquired Infections; Female; Fluoroquinolo | 2005 |
Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Drug | 2006 |
Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxon | 2001 |
13 other studies available for gatifloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
Notes on testing noninferiority in ordinal data under the parallel groups design.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Community-Acquired Infections; | 2013 |
Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).
Topics: Anti-Infective Agents; Canada; Clinical Trials as Topic; Community-Acquired Infections; Dose-Respons | 2002 |
Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Clinical Trials as Topic; Community-Acquir | 2002 |
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Brazil; Community-Acquired Infection | 2003 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Comb | 2004 |
Antimicrobial therapies for pulmonary Klebsiella pneumoniae infection in B6D2F1/J mice immunocompromised by use of sublethal irradiation.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Drug Combinations; Female; Fluoroquinolones; Gatifloxac | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluor | 2004 |
Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin | 2006 |
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Topics: Animals; Anti-Infective Agents; Chlamydia; Chlamydia Infections; Chlamydia trachomatis; Chlamydophil | 1997 |
[Broad-spectrum fluoroquinolones. Passed safety tests up to now].
Topics: Aged; Anti-Infective Agents; Drug Approval; Fluoroquinolones; Gatifloxacin; Germany; Humans; Pneumon | 2001 |
[New quinolone. Better effectiveness in problem cases].
Topics: Anti-Infective Agents; Bronchitis; Fluoroquinolones; Gatifloxacin; Humans; Pneumonia, Bacterial; Tre | 2001 |
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infec | 2002 |
Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Bacteria; Bacterial Infections; Dose-Response Rela | 2002 |